Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex

Shoji, Tetsuaki; Niida, Yo; Osawa, Takahiro; Matsumoto, Ryuji; Sakurai, Kotaro; Suzuki, Masaru; Matsuno, Yoshihiro; Konno, Satoshi

Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex

Shoji, Tetsuaki; Niida, Yo; Osawa, Takahiro et al.

Respiratory Medicine Case Reports, 2021, 34, 101526

Permalink : https://hdl.handle.net/2115/83359

このアイテムのアクセス数:444件（2026-10-15 16:09 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1016/j.rmcr.2021.101526			19

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/83359
タイトル	Resolution of multifocal micronodular pneumocyte hyperplasia with everolimus in a patient with tuberous sclerosis complex
著者	Shoji, Tetsuaki ; Niida, Yo ; Osawa, Takahiro ; Matsumoto, Ryuji ; Sakurai, Kotaro ; Suzuki, Masaru ; Matsuno, Yoshihiro ; Konno, Satoshi
著者名 Shoji, Tetsuaki
著者名 Niida, Yo
著者名 Osawa, Takahiro
著者名 Matsumoto, Ryuji
著者名 Sakurai, Kotaro
著者名 Suzuki, Masaru
著者名 Matsuno, Yoshihiro
e-Rad_Researcher 20399835 著者名 Konno, Satoshi
言語	英語
キーワード	Tuberous sclerosis complex
	Multifocal micronodular pneumocyte
	hyperplasia
	Everolimus
	Surfactant Protein-A (SP-A)
	Surfactant protein-B (SP-B)
発行日	2021-10-06
出版者	Elsevier
収録物名	Respiratory Medicine Case Reports
巻(号)	34
ページ	101526
抄録	A woman with a diagnosis of tuberous sclerosis complex (TSC) presented with TSC2 gene mutation and various manifestations, including epilepsy, renal angiomyolipomas (AML), and pathologically confirmed multifocal micronodular pneumocyte hyperplasia (MMPH). With oral administration of evemlimus, a mammalian target of rapamycin (mTOR) inhibitor, MMPH and AML were markedly reduced. Further, after starting treatment with everolimus, serum levels of surfactant protein (SP)-A and SP-D, which reflect type II pneumocyte hyperplasia, decreased to the normal range. At the time of writing of this manuscript, 6 years after starting evemlimus, MMPH lesions did not relapse and SP-A/D remained the low levels. This is the first case of evemlimus efficacy shown for histologically confirmed MMPH in genetically determined TSC patient, with time course of serum SP-A and SP-D.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	2213-0071
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1016/j.rmcr.2021.101526